Tahara M, Greil R, Rischin D, Harrington KJ, Burtness B, de Castro G, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Lin J, Gumuscu B, Lerman N, Soulières D (2025)
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
Eur J Cancer, 221, 115395
DOI 10.1016/j.ejca.2025.115395, PubMed 40262400

Eriksen JG, Maare C, Johansen J, Primdahl H, Bratland Å, Kristensen CA, Andersen M, Alsner J, Overgaard J, DAHANCA (2025)
DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck
Radiother Oncol, 208, 110899 (in press)
DOI 10.1016/j.radonc.2025.110899, PubMed 40258418

Fager A, Samuelsson M, Olofsson Bagge R, Pivodic A, Bjursten S, Levin M, Jespersen H, Ny L (2025)
Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases
BJC Rep, 3 (1), 22
DOI 10.1038/s44276-025-00137-2, PubMed 40217072